Trial Profile
Phase II, Multi-center, Randomized, Open-label, Parallel-group, Active Controlled Study for the Efficacy and Safety of Pegylated Recombinant Consensus Interferon Variant Solution for Injection in the Treatment of Chronic Hepatitis C
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Peginterferon alfacon-1 (Primary) ; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Beijing Kawin Technology Share-Holding
- 19 Oct 2014 Status changed from active, no longer recruiting to completed, as per ClinicalTrials.gov record.
- 02 Aug 2013 New trial record